Historical Background
Discovered as a hypotensive agent present in urine (Abelous and Bardier 1909; Frey and Kraut 1928). Hypotensive effect later assigned to release of vasodilator peptides, kinins, through enzymatic hydrolysis of protein precursors, kininogens (discovery of the enzymatic activity of kallikrein, Werle 1937).
First cloning of KLK1 gene in the mouse and description of the kallikrein gene family, followed by the rat and human kallikrein gene families, all subsequently expanded (Mason et al. 1983, Lundwall et al. 2006).
Inactivation of the KLK1 gene in the mouse (Meneton et al. 2001).
Description of the genetic determinism of urinary K1 activity in man and elucidation of its molecular basis (Zinner et al. 1976; Slim et al. 2002).
Kallikrein-K1 or tissue kallikrein should not be confounded with another enzyme called “plasma kallikrein” (KLKB1),...
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abelous JE, Bardier E. Les substances hypotensives de l’urine humaine normale. CR Soc Biol. 1909;66:511–20.
Azizi M, Boutouyrie P, Bissery A, Agharazii M, Verbeke F, Stern N, et al. Arterial and renal consequences of partial genetic deficiency in tissue kallikrein activity in humans. J Clin Invest. 2005 Mar;115(3):780–7.
Azizi M, Emanueli C, Peyrard S, Maddedu P, Alhenc-Gelas F, Campbell DJ. Genetic and dietary control of plasma tissue kallikrein secretion and urinary kinins excretion in man. J Hypertens. 2008 Apr;26(4):714–20.
Bergaya S, Meneton P, Bloch-Faure M, Mathieu E, Alhenc-Gelas F, Levy B, Boulanger C. Decreased flow-dependent dilatation in carotid arteries of tissue kallikrein-knockout mice. Circ Res. 2001;88(6):593–9.
Berry TD, Hasstedt SJ, Hunt SC, Wu LL, Smith JB, Ash KO, et al. A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension. 1989 Jan;13(1):3–8.
Bodin S, Chollet C, Goncalves-Mendes N, Gardes J, Pean F, Heudes D, et al. Kallikrein protects against microalbuminuria in experimental type I diabetes. Kidney Int. 2009 Aug;76(4):395–403. doi:10.1038/ki.2009.208.
Desposito D, Waeckel L, Potier L, Richer C, Roussel R, Bouby N, Alhenc-Gelas F. Kallikrein(K1)-kinin-kininase (ACE) and end-organ damage in ischemia and diabetes: therapeutic implications. Biol Chem. 2016 Dec 1;397(12):1217–22. doi:10.1515/hsz-2016-0228.
Frey EK, Kraut H. Ein neues Kreislaufhormon und seine Wirkung. Naunyn-Schmiedeberg’s Arch Exp Pathol Pharmakol. 1928;133:1–12.
Griol-Charihbili V, Messadi-laribi E, Bascands JL, Heudes D, Meneton P, Giudicelli JF, et al. Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia. FASEB J. 2005 Apr;19(9):1172–4. doi:10.1096/fj.04-3508fje.
Kayashima Y, Smithies O, Kakoki M. The kallikrein-kinin system and oxidative stress. Curr Opin Nephrol Hypertens. 2012 Jan;21(1):92–6. doi:10.1097/MNH.0b013e32834 d54b1.
Koid SS, Ziogas J, Campbell DJ. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism. Hypertension. 2014 Apr;63(4):768–73. doi:10.1161/HYPERTENSIONAHA.113.02902.
Lundwall A, Band V, Blaber M, Clements JA, Courty Y, Diamandis EP, et al. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem. 2006 Jun;387(6):637–41.
Margolius HS. Tissue kallikreins and kinins: regulation and roles in hypertensive and diabetic diseases. Annu Rev Pharmacol. 1989;29:343–64.
Mason AJ, Evans BA, Cox DR, Shine J, Richards RI. Structure of mouse kallikrein gene family suggests a role in specific processing of biologically active peptides. Nature. 1983;303:300–7.
Meneton P, Bloch-Faure M, Hagege AA, Ruetten H, Huang W, Bergaya S, et al. Cardiovascular abnormalities with normal blood pressure in tissue kallikrein-deficient mice. Proc Natl Acad Sci U S A. 2001 Feb 27;98(5):2634–9.
Pathak M, Wong SS, Dreveny I, Emsley J. Structure of plasma and tissue kallikreins. Thromb Haemost. 2013 Sep;110(3):423–33. doi:10.1160/TH12-11-0840.
Slim R, Torremocha F, Moreau T, Pizard A, Hunt SC, Vuagnat A, et al. Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity. J Am Soc Nephrol. 2002;13:968–76.
Stone OA, Richer C, Emanueli C, van Weel V, Quax PH, Katare R, et al. Critical role of tissue kallikrein in vessel formation and maturation: implications for therapeutic revascularization. Arterioscler Thromb Vasc Biol. 2009 May;29(5):657–64. doi:10.1161/ ATVBAHA.108.182139.
Waeckel W, Potier L, Richer C, Roussel R, Bouby N, Alhenc-Gelas F. Pathophysiology of genetic deficiency in tissue kallikrein activity in mouse and man. Thrombosis-Haemostasis. 2013 Sept;110(3):476–83. doi:10.1160/TH12-12-0937.
Werle E. Uber die Wirkung des Kallikreins auf den isolierten Darm und uber eine neue darmkontrahierende Substanz. Biochem Z. 1937;289:217–33.
Zinner SH, Margolius HS, Rosner B, Keiser HR. Kass EH Familial aggregation of urinary kallikrein concentration in childhood. Am J Epidemiol. 1976;104:124–32.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this entry
Cite this entry
Alhenc-Gelas, F. (2018). Kallikrein-K1. In: Choi, S. (eds) Encyclopedia of Signaling Molecules. Springer, Cham. https://doi.org/10.1007/978-3-319-67199-4_101810
Download citation
DOI: https://doi.org/10.1007/978-3-319-67199-4_101810
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-67198-7
Online ISBN: 978-3-319-67199-4
eBook Packages: Biomedical and Life SciencesReference Module Biomedical and Life Sciences